Functional effects of drugs and toxins interacting with NaV1.4

NaV1.4 is a voltage-gated sodium channel subtype that is predominantly expressed in skeletal muscle cells. It is essential for producing action potentials and stimulating muscle contraction, and mutations in NaV1.4 can cause various muscle disorders. The discovery of the cryo-EM structure of NaV1.4 in complex with β1 has opened new possibilities for designing drugs and toxins that target NaV1.4. In this review, we summarize the current understanding of channelopathies, the binding sites and functions of chemicals including medicine and toxins that interact with NaV1.4. These substances could be considered novel candidate compounds or tools to develop more potent and selective drugs targeting NaV1.4. Therefore, studying NaV1.4 pharmacology is both theoretically and practically meaningful.


Introduction
residues, Asp/Glu/Lys/Ala (DEKA), at the corresponding locus in the SF of each repeat, determine Na + selectivity (Favre et al., 1996).The loop between DIII and DIV contains the fast inactivation gate with a hydrophobic IlePheMet (IFM) motif that plugs the intracellular mouth of the pore to stop the Na + current following channel activation (Patton et al., 1992;West et al., 1992;Ulbricht, 2005).The C terminus (CTNa V ; ~200-300 amino acids in length) consists of a five-helix EF-hand-like motif (EFL, helices αI-αV) followed by a long α-helix (helix αVI) (Gardill et al., 2018) and extends into the cytoplasm of the cell where it interacts with several proteins, including the cellular calcium sensor calmodulin (CaM) (Qin et al., 2006).
Na V β-subunits are a group of proteins that are associated with Na V channels.Na V β-subunits comprise five subtypes in humans, namely β1-β4 and β1b, and are encoded by SCN1B-SCN4B (Eijkelkamp et al., 2012).These subunits have a single transmembrane structural domain (β1b deletion) and an IG-like extracellular domain with a molecular mass of approximately 30-40 kDa (Sanchez-Solano et al., 2017).The β1 and β3 subunits interact noncovalently with the α-subunit of the Na V channel, whereas the β2 and β4 subunits are covalently bound to the αsubunit via disulfide bonds.Na V channel β-subunits influence Na V channel function through multiple mechanisms, including modulating their expression on the plasma membrane, affecting their gating properties, mediating cell-cell adhesion, and interacting with other proteins (OMalley and Isom, 2015;Calhoun and Isom, 2014;Angsutararux et al., 2021) (Figure 1).Na V 1.4 channels have a complex gating mechanism that involves resting and opening processes.Na V channels can switch between at least three different states, and possibly more, including closed (resting), open, and inactivated (Catterall et al., 2020).According to the state-dependent blocking theory, sodium channel blockers have varying affinities for distinct conformations and functional states of the channels.Therefore, understanding the pharmacological action and mechanism of drugs and toxins that target the Na V 1.4 channel and obtaining a comprehensive knowledge of the gating mechanism of Na V channels are important (Deuis et al., 2017).When the Na V channel is in the resting or closed state, all four VSDs may be in the "down" state.When the membrane is depolarized, the channels are activated, and they quickly open, allowing the pore domain to connect through S4-S5.This change in the channel conformation allows sodium ions to pass through the pore; however, channel opening is followed by rapid inactivation, which results in a non-conducting inactivated channel state, which then eventually recovers from inactivation back to the resting state (Guy and Seetharamulu, 1986).The rapid inactivation is mediated by the IFM residue, which are the residues of the S4-S5 linker binding the pore domain, thereby closing the channel (Chanda and Bezanilla, 2002;Payandeh et al., 2011).
Na V 1.4-associated channelopathies are dominant diseases that affect skeletal muscle excitability and are classified into two opposite groups: non-dystrophic myotonia (NDM) and periodic paralysis (PP), defined by their prevalent clinical symptoms (Nicole and Fontaine, 2015).NDMs are conditions that cause muscle stiffness upon voluntary movement due to delayed skeletal muscle relaxation.This group includes sodium channel myotonia (SCM) and paramyotonia congenita (PMC).PP is characterized by episodic muscle weakness often related to potassium levels.It includes hyperkalemic (HyperPP) and hypokalemic periodic paralysis (HypoPP) (Cannon, 2018).Table 1 presents the main categories of Na V 1.4 skeletal muscle channelopathies, describes the clinical phenotypes, triggers, Na V 1.4 mutations and newly identified pathogenic mutations, as well as the clinically preferred therapeutic agents associated with muscle disorders.
In this review, we summarize the ion channel diseases caused by Na V 1.4 gene mutation, as well as clinical treatment options, drugs and toxins sensitive to Na V 1.4 channels.We focus on the binding sites of this channel with these drugs and toxins, and analyze how they regulate the activity of Na V 1.4.The development and research progress of new drugs for the treatment of Na V 1.4 channel diseases are further discussed.The purpose of this review is to have a more comprehensive and macroscopic understanding of the pharmacological properties of human Na V channels and Na V 1.4, and to provide new treatment ideas and directions for these channel diseases.

Sodium channel blockers for the treatment of NDM
A possible method of managing NDM is to administer sodium channel blockers that can lower the excessive firing of action potentials in overactive muscle fibers.These sodium channel blockers used in clinical settings include anti-arrhythmics (De Bellis et al., 2017), local anesthetics (LAs), and antiepileptics (De Bellis et al., 2023); however, these are not selective for Na V 1.4 and can affect all sodium channels.Therefore, improving the understanding of molecular binding mechanisms and structural designs to identify more effective compounds with fewer side effects that can target Na V 1.4 is crucial (Peschel et al., 2020).

Anti-arrhythmics, the most commonly used treatment for NDM in clinical practice
Anti-arrhythmic drugs belong to sodium ion channel blockers and are widely used in clinical practice.These blockers are also used to treat NDM.Anti-arrhythmic drugs block Na currents (I Na ) in a use-dependent manner.Use-dependent refers the drugs are more effective when the muscles are in use or related ion channels are in activation or inactivation state.As result, they can reduce the action potentials triggered by muscle stiffness and the frequency of muscle membrane depolarization, thus achieving therapeutic effects.Therefore, the higher frequency of muscle membrane depolarization (e.g., muscle stiffness) and the faster heart rate (e.g., ventricular fibrillation), the greater blocking effect appear, with anti-arrhythmic drugs exerting effects specifically on the muscle-tonic discharge of the action potential (Desaphy et al., 2021).Mexiletine (Mex), a class IB anti-arrhythmic medicine, is considered as the first-line drug for treating NDM among antiarrhythmic drugs (De Luca et al., 1997).In 2012, a randomized, double-blind, placebo-controlled 2-period crossover study on Mex in the treatment of 59 NDM patients was published (Statland et al., 2012), which showed that the use of Mex improved varying degrees of stiffness in patients after 4 weeks of treatment.This result also confirms the above viewpoint.It binds mainly to DIII S6 and DIV S6 in the pore domain structure of the sodium channel, which extends its refractory period by delaying the recovery from the inactive state (De Bellis et al., 2017).This also explains that Mex, like the muscle relaxant methylamine, has a dose-dependent effect on inhibiting resting muscle spindle discharge at low concentrations (Zhang et al., 2021a;Watkins et al., 2022).Interestingly, regardless of the origin of the gene mutation that causes NDM, it has a certain efficacy; however, mutations themselves can alter the sensitivity of this channel to Mex (De Bellis et al., 2023).For example, in 2012, two patients with NDM and severe neonatal paroxysmal laryngospasm (SNEL) with the SCN4A G1306E mutation (Figure 2) responded well to Mex administration (Caietta et al., 2013).In a study back in 2001, it was indicated that the G1306E mutation may reduce the blocking effect of Mex (Desaphy et al., 2001).Nevertheless, Mex remains the primary drug for the treatment of NDM on the longterm safety and Mex also confirms its important role in the treatment of NDM diseases (Suetterlin et al., 2015).
To design better Na V 1.4 selective blockers, there is a need to understand the structure of compounds that block Na V 1.4 more specifically.One common approach is to use Mex-like analogs that modify the spatial site resistance of Mex to the binding site as templates for other sodium channel blockers (De Bellis et al., 2013).For example, compared with Mex, sulfurized and chlorinated compounds with a lipophilic aromatic phenyl group substituted for the methyl group on the asymmetric carbon atom of Mex are 10and 20-fold more effective in producing the tonic blocks, respectively.Due to the increase in lipophilicity, their usedependence is reduced (De Luca et al., 2003).However, Mex and its analogues often cause side effects such as dyspepsia, which limits  (Loussouarn et al., 2015;Maggi et al., 2021).

Diseases Function Triggers
Specific feature New mutations Treatment their clinical dosage and sometimes makes them unsuitable for some patients with NDM (Modoni et al., 2020), who may need other sodium channel blockers as alternative treatment.
Tocainide is a class IB anti-arrhythmic drug.It is also one of the few drugs that can reduce the symptoms of tonic syndrome, a condition that causes muscle stiffness and spasms.Some studies have reported that tocainide can effectively treat patients with PMC, a rare form of tonic syndrome, at low doses (Streib, 1987).However, tocainide poses a high risk of severe side effects such as agranulocytosis and anemia (Soff and Kadin, 1987); thus, there is a need to develop new variations of tocainide that are safer and more specific for antimyotonic purposes.One way to achieve this goal is to modify the proline part of tocainide, in which the asymmetric carbon atoms are constrained to rigid α-proline cycle.The tocainide derivative, To5, is 5 and 21 times stronger than tocainide in producing tetanic and 10 Hz-use-dependent blockade of skeletal muscle sodium current, respectively, and has better therapeutic potential.(Talon et al., 2001).N-benzylated β-proline derivatives have been proved to be the most effective use-dependent blocker of heterologous expression of hNa V 1.4; therefore, determining the sites and characteristics of its specific binding with Na V 1.4 is crucial for exploring potential candidate drugs in the existing Pharmacopoeia (De Luca et al., 2012).
Flecainide, often used for its blocking effects on the cardiac Na + channel, belongs to the IC type of anti-arrhythmic drugs similar to Mex (Nitta et al., 1992).A case of a girl with the SCN4A G1306E mutation and SNEL who did not respond to Mex but improved with flecainide was reported in 2016 (Portaro et al., 2016).Desaphy et al. (2004) showed that flecainide could block sodium ion currents in SCN4A wild-type (WT), G1306E, and R1448C (PMC) mutations in an interdependent manner, but it is more effective against R1448C (Figure 2).This phenomenon also confirmed that even though flecainide and Mex exhibit the same blocking mechanism of the skeletal muscle sodium channel, drug selection could be determined by the gating defect caused by individual mutations, especially the specific voltage dependence of sodium channel availability.
In 2007, propafenone, a different type of IC anti-arrhythmic medication, was shown to be effective in treating patients with PMC and significantly reduced the clinical symptoms of cold-induced muscle stiffness (Alfonsi et al., 2007).Subsequently, Farinato et al. (Farinato et al., 2019) pharmacologically characterized tonic Na V 1.4 mutations using different drugs and found that most mutations had decreased sensitivity to Mex and, unexpectedly, did not have an altered response to flecainide and propafenone.However, some clinical results raised the possibility of a link between skeletal muscle and cardiac sodium channelopathies.Therefore, anti-arrhythmic drugs such as flecainide and propafenone should be used with caution in patients with myotonia (De Bellis et al., 2017).

LAs have great potential for the treatment of NDM
The analysis of the structure from crypto-electron microscope has revealed that, the same as other subfamily of Na V channels, Na V 1.4 channel has VSD and pore domain, which is structured by its four S6 segments from its four different domains (Pan et al., 2018).LAs with a hydrophobic ring and an alkaline amine can penetrate the cell membrane and block the channel from inside of cells by binding the pore region to achieve its tonic inhibition on Na V 1.4 channel.In 2005, Lipkind and fozzard (Lipkind and Fozzard, 2005) conducted molecular modeling of Na V 1.4 and LAs, revealing LAs could bind with Leu-1280 (DIII S6) and Phe-1579 of DIV S6 with its alkaline amine.In addition, tits aromatic ring could interact with Tyr-1586 of DIV S6 and Asn-434 of DI S6.Further research has found that LAs have different blocking effects on different Na V channels.Scholz group found that TTX sensitive (TTX-s) Na V channels, which can be blocked by TTX and their IC 50 s of TTX is in single digit nano-molar range, were more susceptible to LAs than TTX resistant (TTX-r) Na V channels including Na V 1.8 and Na V 1.9.For example, the half maximum inhibitory concentration (IC 50 ) of lidocaine for tetanic block of TTX-r Na + current is 5 times stronger than that of TTX-s (Scholz et al., 1998).In 2016, Gingrich and Wagner group (Gingrich and Wagner, 2016) reported that lidocaine regulated the Na + current of rNa V 1.4 (rat Na V 1.4) channel by blocking the channel at open state, which is the second high affinity block comparing with the highest affinity block at inactivation state.Although there are few examples and literatures on the clinical use of LA drugs (LAs) in the treatment of NDM, there is no doubt that they have effects on NDM as LAs are sodium channel.We speculate the side effects of LAs preventing its clinic application of NDM.Through indepth study of the interaction mechanism between local anesthetics and Na V 1.4 channel, we can still be benefit by better understanding its mechanism of action, which provides more theoretical support for clinical practice and new drug development.

Antiepileptics have therapeutic effects on patients with Mex intolerance
Antiepileptic drugs are usually neutral in charge, unlike LA drugs, which are primarily cationic.However, both antiepileptic and LA drugs can interact with critical residues in the DIV S6 of Na V 1.4 (Ragsdale et al., 1996) and block the channel with similar affinity regardless of state, i.e., open or inactive.This hypothesis was confirmed by Buyan et al. (2021), who used molecular dynamics (MD) simulations to compare the binding modes of the two drug classes.They also discovered that the Y1593 residue in Na V 1.4 was essential for drug binding (Lipkind and Fozzard, 2010).The blockade mechanism involves the aromatic ring of antiepileptics almost perpendicularly inserting into the pharmacophore, occupying the pore cavity.This may cause interactions with other S6 fragments and physically obstruct the inner pore, preventing Na + from entering (Lipkind and Fozzard, 2010).Phenytoin, carbamazepine, and lamotrigine are relatively common antiepileptic drugs.Lamotrigine has a particularly good therapeutic effect for patients who do not respond or are intolerant to Mex, as shown by clinical trials (Andersen et al., 2017;Vereb et al., 2021).Other antiepileptics, such as lacosamide and rufinamide, can also reduce myotonia in isolated human and rat skeletal muscles, but they have different inhibitory concentrations (Skov et al., 2017).In 2021, a cannabinoid from the cannabis plant, cannabidiol (CBD), was reported to relieve myotonia caused by sodium channelopathy, especially when the channel is in its slow inactivation state, owing to its high binding affinity for Na V 1.4 channels (Huang et al., 2021).Ghovanloo et al. (2021) also studied the localization of CBD in the membrane using MD simulation and nuclear magnetic resonance and found that CBD could reduce the excitability of the Na V 1.4 P1158S mutant (associated with NDM and PP).This suggests that CBD may have therapeutic potential for ion channel diseases with Na V 1.4 hyperexcitability (Ghovanloo et al., 2021) (Figure 3).

Pharmacological treatment of primary PP caused by the SCN4A mutation
Primary PP is a rare autosomal dominant genetic disorder that affects the sodium channel Na V 1.4 gene in skeletal muscle, leading to Hyper-or HypoPP.These conditions are characterized by episodes of muscle weakness or paralysis triggered by changes in potassium levels or other factors.The muscle membrane becomes depolarized, and the sodium channel becomes inactive, reducing the ability of muscles to contract (Finsterer, 2008).The current treatment options are mainly preventive and symptomatic, involving dietary and lifestyle changes, potassium supplementation or restriction, and drugs such as carbonic anhydrase inhibitors (CAIs), including acetazolamide (Sansone et al., 2008) and diclofenamide (Sansone et al., 2016), and diuretics (Venance et al., 2006;Statland et al., 2018).These treatments aim to avoid or reverse attack triggers and restore muscle function.

The main clinical treatments for HyperPP
SCN4A mutations account for more than 50% of HyperPP cases (Venance et al., 2006).HyperPP is a disorder that affects the sodium channels in muscle cells, leading to abnormal sodium influx and muscle depolarization.This results in symptoms of myotonia (Maggi et al., 2020) or PP (Hayward et al., 1999).Most HyperPP mutations occur in the DIII-DIV structural domain (inactivation gate) of the sodium channel (Rojas et al., 1991;Sillen et al., 1996).HyperPP causes temporary muscle weakness or paralysis when blood potassium levels are high.Usually, HyperPP does not require any medication, but some people may benefit from using an inhaler with salbutamol, which induces hyperpolarization of the muscle membrane through stimulation of Na + /K + pumps, terminating acute episodes of paralysis (Hanna et al., 1998).To prevent HyperPP episodes, some drugs, including CAI drugs and thiazide diuretics (hydrochlorothiazide), can be used to keep blood potassium levels low.NormoPP is a subtype of HyperPP that occurs even when blood potassium levels are normal (Chinnery et al., 2002).In 2018, a study showed that hydrochlorothiazide was very effective in treating NormoPP caused by the T704M mutation of SCN4A without any side effects (Akaba et al., 2018).However, whether the therapeutic response of these drugs depends on the genetic cause of HyperPP is unclear.

Typical drug therapy for HypoPP
HypoPP2 is a subtype of HypoPP that accounts for 20% of cases and results from mutations in the SCN4A gene encoding the Na V 1.4 channel (Jurkat-Rott et al., 2000).These mutations affect the S4 segment of the VSD, resulting in the left shift in the steadystate inactivation curve and enhancing voltage sensitivity (Groome et al., 2014), and cause longer episodes of weakness than those in HyperPP without NDM features (Matthews et al., 2009).The most striking physiological feature is flaccid skeletal muscle paralysis with reduced serum potassium levels.CAIs can prevent attacks, but acetazolamide (ACZ) might worsen PP in patients with diabetes and has little effect on HypoPP2 (Ikeda et al., 2002;Matthews et al., 2011).Potassium-sparing diuretics (eplerenone or spironolactone) are an alternative for patients who do not respond to or tolerate CAIs (Weber and Lehmann-Horn, 1993).However, the exact mechanism of the interaction of these drugs and Na V 1.4 is unknown.Therefore, new genotype-based drugs are needed for better treatment (Tricarico et al., 2006).

Ranolazine may be the most promising drug for treating congenital myasthenic syndrome
Congenital myasthenic syndrome (CMS) is a group of rare disorders that affect the transmission of signals between nerve and muscle cells.One of the causes of CMS is mutations in ion channels.Habbout et al. (2016) reported a new case of CMS caused by a recessive mutation in the SCN4A gene, which leads to congenital myopathy with PP (Habbout et al., 2016).However, knowledge of how to effectively treat this type of CMS is limited.Larusso et al. ( 2019) explored the use of three drugs targeting sodium channels: Mex, lacosamide, and ranolazine.They tested these drugs on a mouse model of congenital hypotonia, a disorder that causes low muscle tone and weakness.Ranolazine was the most potent drug and had the fewest side effects, suggesting that it could be a promising candidate for treating CMS and other congenital myopathies (Lorusso et al., 2019).
5 Some toxins specifically target and block the VSD and PM of Nav1.4Recent studies have revealed that various venomous compounds, such as scorpion α-toxins, can interact with specific Na V channel subtypes in various biological systems (Bosmans and Tytgat, 2007).These toxins are commonly used to capture prey or for defense.Organisms employing these toxins include pufferfish, seaweed, scorpions, spiders, and conical snails (Maatuf et al., 2019).Some of these toxins are sodium ion channel blockers (De Bellis et al., 2017), and others are channel activators (Deuis et al., 2017).Among the most typical closed pore blockers are TTX and saxitoxin (STX) (West et al., 2002;Cervenka et al., 2010), as well as compounds that extend channel activation by altering gating after binding to the pore, such as veratridine (VTD).The VSD of DII was identified as a major component of the neurotoxin receptor site.

Neuropeptide toxins
TTX, a natural cyclic guanidinium salt neurotoxin, is a potent neurotoxin that blocks the sodium channels of nerve cells.The nine types of Na V channels in mammals can be classified into two groups based on their sensitivity to TTX: TTX-sensitive (TTX-s) and TTXresistant (TTX-r).The TTX-s channels (Na and Na V 1.7) are inhibited by low TTX concentrations, while the TTX-r channels (Na V 1.5, Na V 1.8, and Na V 1.9) are unaffected by TTX or require very high doses to be blocked.In 1985, Gonoi et al. (1985) discovered that rat skeletal muscle cells had both types of channels, and they could be distinguished using colchicine to induce muscle ball formation.The skeletal muscle Na V 1.4 channel was TTX-s, and its blockade by TTX prevented the generation of an action potential (Gonoi et al., 1985).TTX binding to the TTX-s channels depends on specific amino acid residues in the pore region of the channel, and mutations in these residues can reduce or abolish the affinity of TTX for the channel (Noda et al., 1989;Terlau et al., 1991;Boccaccio et al., 1999). In 1992, Satin et al. (1992) and Backx et al. (1992) showed that TTX binds with high affinity to channels that have aromatic residues (Phe or Tyr) at specific sites in the outer pore vestibule (Backx et al., 1992;Satin et al., 1992).Santarelli et al. (2007) investigated the role of these residues in the TTX-s Na V 1.4 channel and found that they interacted directly with the guanidine group of TTX through π -cation bond attraction to conservative Tyr or Phe in the TTX-s Na V 1.4 channel.This explains the preference of TTX for channels with aromatic residues and the mechanism of TTX sensitivity considering cation bonds.
STX is a biguanide neurotoxin that is synthesized by the marine dinoflagellate Gymnodinium catenatum.Similar to TTX, STX binds strongly to the external vestibule of the Na V channel, blocking the permeation pathway and competing with TTX for the binding sites.However, they differ in that STX has post-repolarization blocking and frequency-dependent blocking effects and an increased blocking effect with higher frequency (Rando and Strichartz, 1986).Furthermore, STX exhibits shorter binding and dissociation rates (Lonnendonker, 1989).Notably, the latest STX derivatives identified by Pajouhesh et al. (2020) displayed promising analgesic activity in clinical settings.In addition, Duran-Riveroll et al. (2016) reported a benzoyl analog of STX and performed theoretical docking simulations of STX and the identified analog with two alternative three-dimensional models based on Na V 1.4.
Spider venom is particularly enriched in Na V modulators, but not all of them affect Na V 1.4, e.g., hainantoxin-III (Zhang et al., 2021b).Generally, spider venom peptides interact with DIV to delay rapid inactivation, while peptides that bind with DI-III cause a voltage-dependent channel opening and closing shifts (Bosmans et al., 2008).Spider peptides are useful for identifying Na V 1.4 and developing potential Na V channelopathy therapies.A study by Moyer et al. (2018) showed that a 28-residue Ile mutant of the Na V 1.7 toxin peptide JzTx-V (from the spider Chilobrachys jingzhao) had a 100-fold higher selectivity for the skeletal muscle Na V 1.4 channel and blocked it effectively.Chen et al. (2020) observed that recombinant spider venom PaurTx-3 (rPaurTx-3) also inhibited Na V 1.4 current with a half maximal inhibitory concentration (IC 50 ) value of 61 nM.These spider venom peptides with Cys functional sites have unique pharmacological properties that make them attractive candidates for new therapies for skeletal muscle-nervous system diseases, as well as serving as drug precursors (Cardoso and Lewis, 2019).
Scorpion neurotoxins that target Na V channels can be classified into two types: αor β-toxins (Zhu et al., 2004).Under normal circumstances, α-toxins delay the fast inactivation of Na V channels (Martin-Eauclaire et al., 2019).β-Scorpion toxins alter the activation threshold and reduce the peak current (Couraud et al., 1982).Researchers have been developing scorpion toxin derivatives for various purposes.For instance, Xu et al. (2020) modified the Trp38 residue of the purified scorpion toxin AGAP, a crucial residue for binding AGAP to the sodium channel, and found that the mutants reduced the inhibitory effects of AGAP on hNa V 1.4 and analgesic effects on skeletal muscle.Additionally, Tz1, the main component of the venom from the Nerella scorpion (Tityus zulianus), alters the voltage dependence of Na V 1.4 channel activation (Leipold et al., 2006), which could help identify other peptide toxins with pharmacological properties in scorpion venom.
μ-Conotoxin (μ-CTx), isolated from the venom of the cone snail (Conus spp.), has a unique structure with three disulfide bonds forming a type III cysteine motif (CC-C-C-CC).This toxin is an effective and selective blocker of the Na V channel, wherein GIIIA, PIIIA, and SxIIIC selectively inhibit Na V 1.4, mainly expressed in skeletal muscle, with IC 50 values in the nanomolar range.Using μ-CTx GIIIA as a probe, Li et al. (2001) uncovered the clockwise orientation of the four structural domains of Na V channels.Chen et al. (2014) investigated the effects of TTX, m-conotoxin DI-Asn181, and DIV-Glu172 on the Na V 1.4 channel, which is involved in muscle contraction.They found that these toxins had different selectivity for the PIIIA isoform of Na V 1.4, which is resistant to TTX.By introducing mutations (DI-N181R, DIV-E172Q) to the toxins, their affinity for PIIIA increased relative to that of TTX.A new μ-CTx toxin, SxIIIC, belonging to a class of conotoxins with hydroxyproline and high tissue specificity, was discovered by McMahon et al., in 2020.It can inhibit Na V 1.4 in human skeletal muscle at an IC 50 of approximately 15 nM but does not affect other Na V channel subtypes and selectivity for Na V 1.4 is about 10 times higher than that for other Na V channels (MCMahon et al., 2020).Therefore, SxIIIC may be a promising drug candidate for diseases related to Na V 1.4 dysfunction.The toxin-binding ion channel structure can help in the design of drugs targeting specific channels, and the toxin itself can be a useful drug or a model for drug development.We will discuss how toxins have inspired new ion channel toxins for pain relief.These modulators may also treat muscle and nerve disorders in the future.

Potent alkaloid toxins
Na V channel biophysical properties are affected by different alkaloids.These alkaloids can alter specific Na channel functions and are useful as pharmacological probes to study the Na channel functional structure.Lipid-soluble toxins, such as grayanotoxin (GTX), batrachotoxin (BTX), VTD, and aconitine (AC), have some common characteristics: they bind to open Na channels, prevent Na channel inactivation, and shift the Na channel activation voltage to more hyperpolarized potentials (Khodorov, 1985;Narahashi and Herman, 1992).The binding sites of these toxins may include amino acids that are crucial for both activation and deactivation gating mechanisms.
BTX is a lipophilic steroidal alkaloid derived from the skin secretions of tree frogs (Phyllobates spp.).BTX affects Na V channels by binding to their open state and shifting their activation voltage to more negative values, irreversibly promoting activation and inhibiting both rapid and slow inactivation.The binding site of BTX is in the inner pore region of Na V , where it prevents the necessary S6 rearrangement required for closing the channel after activation by binding at the level of its gated hinge residues, resulting in persistent sodium influx and muscle contraction (Li et al., 2002).Therefore, BTX is a potent toxin that inhibits the fast inactivation of rNa V 1.4 (Bosmans et al., 2004;Logan et al., 2016).Ginsenoside Rg3 is a natural compound that can inhibit the effect of BTX on rNa V 1.4 by competing for the same binding site.In 2008, Logan et al. (2016) showed that ginsenoside Rg3 reduced the BTX sensitivity of WT rNa V 1.4 expressed in Xenopus oocytes, with an IC 50 of 58.5 µM.They also identified a critical residue, L437, that was essential for both BTX and ginsenoside Rg3 binding.Mutating L437 abolished the ginsenoside Rg3 inhibition of rNa V 1.4, indicating that L437 is a key determinant of the interaction between BTX and rNa V 1.4 (Lee et al., 2008).Their study provides molecular insights into the mechanism of action of BTX and ginsenoside Rg3 on rNa V 1.4 channels.
GTX is a type of diterpenoid compound that exists in the leaves, fine branches, and flowers of azaleas.Similar to BTX, GTX inhibits fast inactivation and alters ion selectivity, but it also reduces peak currents (Kimura et al., 2000).GTX has low potency with a median effect concentration (IC 50 ) of 31 μM, and it affects the TTX-r Na + channel (dorsal root ganglion cells) more than other sodium channels.However, GTX analogs have less impact on TTX-s and cardiac Na + channels (Yakehiro et al., 1997;Yakehiro et al., 2000).Recent studies on GTX have focused on evaluating its activity against rNa V 1.4 channels (Deuis et al., 2017).
VTD is a steroid-derived alkaloid from the roots of Veratrum of the Liliaceae family that affects sodium channels in cells.VTD can keep the Na V channel open without repeated stimulation under voltage-clamp conditions (Ghatpande and Sikdar, 1999).Wang and Wang showed that VTD and LAs bind to similar sites inside the Na V channel, and the receptor of bound VTD may be located in the internal vestibule, but the exact location is still unclear (Wang and Wang, 2003).Since the mutants were overly sensitive to the VTD inhibition of the Na V peak current, they have been commonly used as Na V channel activators for fluorescence identification (Vickery et al., 2004;Deuis et al., 2017).
AC is a steroid-derived alkaloid found in the plant A. napellus.It is a neurotoxin that binds to the neurotoxin-binding receptor site II on the Na V α-subunit.This interaction prolongs the opening of the sodium channels, causing nerve stimulation and, eventually, paralysis (Rao and Sikdar, 2000).AC, renowned for its high cardiotoxicity, is often used to establish rat arrhythmia models (Zhao et al., 2013).A recent study by Imai et al. (2020) showed that goshajinkigan (GJG), an herbal medicine containing A. napellus, could inhibit Na V 1.4 currents in C2C12 cells with an IC 50 of approximately 73.13 µg/mL.They also reported that GJG could alleviate skeletal muscle stiffness and spasticity and speculated that Na V 1.4 current inhibition was mainly due to AC (Imai et al., 2020).AC has similar effects on Na V 1.4 and Na V 1.5, but its activity on other Na V subtypes needs further confirmation (Deuis et al., 2017).

Conclusion and outlook
In summary, Na V 1.4 is the most prominent channel that regulates skeletal muscle contraction and is affected by various drugs and toxins (Table 2).The molecular structure of Na V 1.4 has been partially  elucidated, but more studies are required to reveal its biochemical, molecular, physiological, and pharmacological aspects.A better understanding of Na V 1.4 function will facilitate the discovery of new therapies for Na V 1.4 channelopathies that are specific and safe.Moreover, Na V 1.4 modulators derived from drugs and toxins may have great potential as research tools or clinical agents.The results of this article contribute to recognition and awareness of ion channels and a deeper understanding of the importance of Na V channels in mammalian bodies.Additionally, it will provide insights for the development of channel selective drugs and the prevention of ion channel diseases.

FIGURE 2 Frequency
FIGURE 2Frequency-dependent flecainide blockage of wild-type (WT) and mutant hNa V 1.4 channels at a holding potential of −120 mV.(A) Three minutes after treatment with flecainide, the Na current blockage of WT and mutants was evaluated under different stimulation frequencies.(B,C) Concentrationresponse fitting curve of flecainide on WT and mutants blockage at stimulation frequencies of (B) 0.1 Hz and (C) 10 Hz. (Copyright permission was obtained for the use of these images.)CTRL, Control; GE, G1306E; RC, R1448C(Desaphy et al., 2004).(OrderNumber:5734610752304).

FIGURE 3
FIGURE 3 Effects of cannabidiol (CBD) on Na V 1.4 gating.(A,B) Voltage dependence of activation shown as normalized conductance plotted against membrane potential in 1 µM CBD, and normalized activating currents as a function of potential.(C) Voltage dependence of 200 ms F-I curve plotted against the membrane potential in 1 µM CBD.(D) Recovery from fast inactivation in 1 µM CBD at 500 ms.(E) The slow components of recovery from inactivation in the control and CBD (1 µM) at 500 ms are shown on the left y-axis (logarithmic scale), and the fraction of the slow-to-fast component of recovery from inactivation is shown on the right y-axis.(F) Use-dependent inactivation in control and 2 µM CBD.The normalized current decay is plotted as a function of time fitted with an exponential curve.(G) State-dependent block of the peak Na V 1.4 current at 10 µM.(H) Pulse protocol used for state dependence experiments.Recordings were performed at 1 Hz.(Copyright permission was obtained for the use of these images.)(Ghovanloo et al., 2021) (Order Number: 1453352).

TABLE 1
Clinical phenotypes associated with Na V1.4 mutations

TABLE 2
Binding sites and efficacy of drugs and toxins.